文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-PSMA-617首周期SPECT/CT半定量参数预测晚期mCRPC病灶应答

The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-05-20

该双中心回顾性病灶分析纳入23例mCRPC患者的290个病灶,评估首周期[177Lu]Lu-PSMA-617 SPECT/CT半定量参数与末周期单病灶应答的关系。非进展病灶的首周期TLA、SUVmax、SUVmean、TLV均显著高于进展病灶,其中TLA的AUC最高(0.854)。提示首周期SPECT/CT半定量参数尤其是反映PSMA表达的参数,可能作为RLT单病灶应答的早期预测指标。

要点

  • 首周期SPECT/CT的TLA、SUVmax、SUVmean在非进展病灶中显著高于进展病灶。
  • TLA预测单病灶应答的AUC为0.854,最佳截断值61.7。
  • SUVmax与SUVmean的AUC分别为0.843和0.838,TLV较低为0.612。

核心结论

  • 首周期[177Lu]Lu-PSMA-617 SPECT/CT半定量参数,尤其是反映PSMA表达的参数,可能作为RLT单病灶应答的早期预测指标。

研究设计与样本

  • 回顾性双中心病灶分析,纳入2022年2月至2026年1月在Messina和Genova大学接受至少两周期[177Lu]Lu-PSMA-617治疗的连续mCRPC患者,共23例、290个病灶。
  • 首周期SPECT/CT图像经MIM以40%阈值半自动分割每个PSMA阳性病灶,提取SUVmax、SUVmean、TLV及TLA(TLA=SUVmean×TLV)。

主要发现

  • 290个病灶中249个为骨/骨髓病灶、34个为淋巴结病灶、7个为内脏病灶。
  • 末周期时60个病灶进展、230个病灶稳定或应答。
  • 首周期半定量参数在非进展病灶中显著高于进展病灶:TLA、SUVmax、SUVmean的p<0.001,TLV的p=0.008。

关键数值与推荐

  • ROC分析显示TLA的AUC为0.854(最佳截断值61.7),SUVmax为0.843(最佳截断值11.8),SUVmean为0.838(最佳截断值6),TLV为0.612(最佳截断值7.05mL)。
  • 单病灶应答按定性RECIP 1.0和定量PPP标准的截断值分类为进展或非进展(完全缓解/部分缓解/稳定疾病)。

临床怎么用

  • 对接受[177Lu]Lu-PSMA-617 RLT的mCRPC患者,首周期SPECT/CT半定量参数(尤其TLA、SUVmax、SUVmean)可辅助早期识别可能应答的单病灶。
  • TLV的预测效能较低(AUC 0.612),单独使用价值有限。

局限性

  • 回顾性设计且为初步分析,样本量较小(23例患者)。
  • 研究为病灶水平分析,结论尚需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [¹⁷⁷Lu]Lu-PSMA RLT represents an effective option for advanced mCRPC. SPECT/CT allows the assessment of biodistribution and lesion-level tracer accumulation. We aimed to determine whether semiquantitative RLT SPECT/CT parameters could predict response on a lesion level. METHODS: We retrospectively considered consecutive mCRPC patients who, between February 2022 and January 2026, received minimum two [¹⁷⁷Lu]Lu-PSMA-617 cycles at Messina and Genova Universities, with SPECT/CT at the 1st RLT, including whole PSMA-positive disease. Each [¹⁷⁷Lu]Lu-PSMA-617-positive lesion was semiautomatically segmented using MIM through a 40% threshold to extract SUVmax, SUVmean, Total Lesion Volume (TLV), and Total Lesion Activity (TLA=SUVmean×TLV). Each lesion's semiquantitative parameter was correlated with the single-lesion response at the last RLT cycle, classified as progressive or non-progressive (complete/partial response, stable disease) according to cut-offs from qualitative RECIP 1.0 and quantitative PPP criteria. ROC curves were used to determine the best cutoffs. RESULTS: We included 23 mCRPC patients for a total of 290 lesions: 249 osteomedullary, 34 lymph nodal, and 7 visceral. At the last cycle, 60 out of 290 lesions progressed, while 230 out of 290 remained stable/responded to RLT. 1st cycle [¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters were significantly higher in non-PD than in PD lesions (p < 0.001 for TLA, SUVmax, SUVmean; p = 0.008 for TLV). On ROC analysis, TLA reached an AUC of 0.854 (best cut-off = 61.7), SUVmax 0.843 (best cut-off = 11.8), SUVmean 0.838 (best cut-off = 6), and TLV 0.612 (best cut-off = 7.05mL), respectively. CONCLUSION: Our preliminary findings suggest that 1st cycle [¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters, especially when reflecting PSMA-expression, may serve as promising early predictors of the single-lesion response to RLT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Laudicella R, Celesti G, Bauckneht M, et al. The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42156554. doi:10.1007/s00259-026-07927-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。